| http://www.w3.org/ns/prov#value | - This issue must be fully addressed where pertinent else all key stakeholder groups will lose out??? Pricing, i.e. pharmaceutical companies may be tempted to initially over price their new drug in expectation of price cuts/cost shifting downstream as the evidence base growsOn the other hand, pay-for-performance schemes do encourage pharmaceutical companies to develop biomarkers or other methods tha
|
